Developer docs
API playgroundTry for free, no card

Search company profiles

Variant Bio

Full company profile

uuid0000e7m

Namestring
Variant Bio
Legal namestring
Variant Bio, Inc.
Websiteurl
variantbio.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomics drug discovery, AI-powered therapeutics, therapeutic target identification, multi-omics data analysis, pharmaceutical collaborations
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Genomics Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Licensing & Milestone Payments
TypeLicensing Royalties
Description

Variant Bio enters multi-year research collaborations with pharmaceutical companies (Boehringer Ingelheim, Novo Nordisk, Evotec) to discover and validate drug targets. Revenue is generated through upfront payments, milestone payments tied to research and development achievements, and potential running royalties on net sales of any approved products. The Boehringer Ingelheim deal includes potential payments exceeding $120 million, with total collaborations exceeding $200 million.

variantbio.com
2Platform Access & Data Licensing
TypeSubscription Recurring
Description

Pharmaceutical partners pay for access to the Inference platform to run target discovery programs, generating upfront license fees and ongoing access fees as part of collaboration agreements.

variantbio.com
3Grant Funding
TypeProfessional Services
Description

The company receives grant support for specific research projects, such as a Gates Foundation-funded two-year project to map global variation in immune-related genes. This represents non-dilutive funding for targeted research initiatives.

variantbio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Variant Bio develops life-saving therapies by leveraging human genetic diversity from underrepresented global populations. The company operates the Inference (VB-Inference) agentic AI-powered genomics platform, which integrates whole genome sequencing with deep phenotyping and multi-omics data to identify and validate novel therapeutic targets. It monetizes these discoveries through multi-year research collaborations and licensing agreements with large pharmaceutical companies, earning upfront fees, development milestones, and potential royalties on commercialized products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Drugs supported by human genetics are over twice as likely to succeed in clinical trials
+2 more records
Product overview1 text field

Variant Bio operates as a genomic drug discovery company with the Inference Platform (VB-Inference) as its core AI-powered product. This agentic AI genomics platform integrates whole genome sequencing with deep phenotyping and multi-omics data to identify and validate therapeutic targets. The platform is supported by a network of genomic partnerships with underrepresented populations globally. Variant Bio's therapeutic pipeline includes programs at various stages focused on inflammation, fibrosis, and kidney diseases. The company also provides data generation services using gold-standard platforms (Illumina, Olink, Metabolon) and maintains strategic collaborations with pharmaceutical partners including Boehringer Ingelheim and Novo Nordisk.

Product and service4 records
1Inference Platform (VB-Inference)
CategoryCore Platform / Product
2Therapeutic Pipeline
CategoryTherapeutic Pipeline / Asset
3Data Generation Services
CategoryService
4Genomic Research Partnerships
CategoryService
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Variant Bio entered a multi-year research collaboration and license agreement with Boehringer Ingelheim to discover and validate novel drug targets for cardiorenal and kidney disease using the Inference AI platform. Variant Bio is eligible to receive upfront, license, and milestone payments totaling over $120 million SEK, with total collaborations exceeding $200 million. The partnership leverages Boehringer Ingelheim's extensive expertise in breakthrough medicine R&D.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

Variant Bio launched a multi-year research partnership with Novo Nordisk to identify and validate novel targets with strong genetic evidence for the treatment of metabolic disease. The project leverages Variant Bio's Inference analysis platform and expertise partnering with global populations, as well as Novo Nordisk's vast experience in metabolic disease drug discovery. A notable feature of this partnership is that Novo Nordisk agreed to Variant Bio's benefit-sharing commitments with partner communities.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-04-18
Description

Variant Bio entered a strategic partnership with Evotec to elucidate a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the program toward selection of clinical development candidate(s). The collaboration leverages Variant Bio's cutting-edge genomic discovery capabilities and Inference platform as well as Evotec's extensive expertise in antifibrotic drug discovery.

4University of Antananarivo (Madagascar)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with the Department of Anthropobiology and Sustainable Development led by Dr. Rindra Rakotoarivony, Pr. Germain Jules Spiral, and Dr. Jean Freddy Ranaivoarisoa. Partnership with Malagasy communities from three villages to understand human genetic diversity in Madagascar.

variantbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with the Sydney Brenner Institute for Molecular Bioscience at Wits University, building on the H3Africa AWI-Gen Collaborative Centre. Partnership with communities in Mpumalanga (Agincourt), Gauteng (Soweto), and Limpopo (DIMAMO) to create an eQTL database for understanding gene regulation across South African populations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. June Fabian (Wits Donald Gordon Medical Centre) and co-investigators Profs. Michèle Ramsay and Stephen Tollman. Working with rural communities in Mpumalanga to understand kidney disease burden, causes, and prevention in Sub-Saharan African populations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Bilhi Genetics, founded by Dr. Alain Dessein, to identify genetic risk factors for severe liver fibrosis among communities in the West Nile region of Uganda, where schistosoma parasite infection is highly prevalent.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Professor Vivekanand Jha's Kidney Research Team to investigate the genetics of chronic kidney disease in the Uddanam region of Andhra Pradesh, India, an area with high CKD prevalence.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Drs. Atchayaram Nalini and Gautham Arunachal Udupi for the first population-scale genomic study of ALS in India, aiming to understand frequencies of known genetic variants and discover new variants associated with ALS across Indian ethnic groups.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with the Genome Diversity and Diseases Research Group led by Dr. Herawati Sudoyo and Dr. Safarina Malik. Partnership with communities from six ethnic groups across the Indonesian archipelago and expanded to samples from over 70 ethnic groups, combining genetics, functional genomics, metabolomics, and clinical data.

11FarGen & University of Copenhagen (Faroe Islands)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with FarGen (Faroe Genome Project, managed by Fólkaheilsustýrið) and Dr. Fernando Racimo from the University of Copenhagen. The Faroese population exhibits increased prevalence of cystic fibrosis, autoimmune disorders, and multiple sclerosis. Goal is to create a genetic reference panel representing the Faroese people for precision medicine.

variantbio.com
12University of Otago (Aotearoa New Zealand)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Tony Merriman for studies of metabolic disease (gout, kidney disease, diabetes) in people of Māori and Pacific ancestry, where these conditions are 2-3-fold more prevalent. Also a specific Pukapuka community study in Auckland focusing on genetics of gout and kidney disease.

variantbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Professor Tristan Pascart and the French Polynesian Ministry of Health for a large genetic study of gout across seven islands spanning French Polynesia's five archipelagos. Gout is especially frequent among Indigenous Pacific populations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Professor Lyn Griffiths' Norfolk Island Health Study, expanding into new clinical areas and focusing on determining the burden of kidney disease, its causes, and prevention in the Norfolk Island community.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Tony Merriman and lab members for gout GWAS analyses and therapeutic target validation in gout based on prior genomic studies with Polynesian populations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI platform that mines biomedical and genomic knowledge graphs to surface and validate novel drug targets; comparable AI-for-target-discovery value proposition with pharma partnerships.

TypeEmerging player
Description

AI-biomedicine platform that partners with academic medical centers and pharma to discover targets using multimodal patient data; intersects with Variant Bio's B2B pharma collaboration model.

TypeDirect peer
Description

AI/ML-driven drug discovery company combining machine learning with cellular and genetic data to identify and validate therapeutic targets; pursues pharma partnerships similarly to Variant Bio.

4Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company using computational methods to accelerate target identification and partner with large pharma; direct competitive overlap in AI-genomics for therapeutics.

TypeEmerging player
Description

AI-driven biologic drug creation company combining generative AI with wet-lab validation; overlaps with Variant Bio's computational biology approach to therapeutic development.

TypeDirect peer
Description

AI-driven drug design company with pharma partnerships for target identification and small-molecule design; comparable AI-discovery platform play serving similar pharma customers.

TypeDirect peer
Description

AI-enabled biotech that combines high-throughput biology with machine learning for target discovery and enters multi-year pharma collaborations; overlaps with Variant Bio's enterprise licensing motion.

TypeEmerging player
Description

Generative AI platform for designing novel therapeutic proteins and biologics; partially overlapping in AI-biology-for-drug-discovery with a focus on generative rather than genetics-driven target ID.

TypeDirect peer
Description

Computational chemistry and biology platform serving pharma customers with target prioritization and molecular design; competes for similar pharma AI-discovery budgets.

TypeEmerging player
Description

AI-driven drug discovery using human genomics data to identify targets; comparable genetics-first approach though concentrated in neurodegenerative disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Variant Bio

Genomics Drug Discoveryvariantbio.com

Variant Bio firmographics

Firmographics
Name
Variant Bio
Legal name
Variant Bio, Inc.
Website
https://variantbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Variant Bio industry classification

Industry
Product category
Genomics Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Genomics drug discovery
  • AI-powered therapeutics
  • Therapeutic target identification
  • Multi-omics data analysis
  • Pharmaceutical collaborations

Where Variant Bio is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Variant Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing & Milestone Payments: Variant Bio enters multi-year research collaborations with pharmaceutical companies (Boehringer Ingelheim, Novo Nordisk, Evotec) to discover and validate drug targets. Revenue is generated through upfront payments, milestone payments tied to research and development achievements, and potential running royalties on net sales of any approved products. The Boehringer Ingelheim deal includes potential payments exceeding $120 million, with total collaborations exceeding $200 million.
  2. Platform Access & Data Licensing: Pharmaceutical partners pay for access to the Inference platform to run target discovery programs, generating upfront license fees and ongoing access fees as part of collaboration agreements.
  3. Grant Funding: The company receives grant support for specific research projects, such as a Gates Foundation-funded two-year project to map global variation in immune-related genes. This represents non-dilutive funding for targeted research initiatives.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Variant Bio product offering

Product offering

Core offering

Variant Bio develops life-saving therapies by leveraging human genetic diversity from underrepresented global populations. The company operates the Inference (VB-Inference) agentic AI-powered genomics platform, which integrates whole genome sequencing with deep phenotyping and multi-omics data to identify and validate novel therapeutic targets. It monetizes these discoveries through multi-year research collaborations and licensing agreements with large pharmaceutical companies, earning upfront fees, development milestones, and potential royalties on commercialized products.

Product overview

Variant Bio operates as a genomic drug discovery company with the Inference Platform (VB-Inference) as its core AI-powered product. This agentic AI genomics platform integrates whole genome sequencing with deep phenotyping and multi-omics data to identify and validate therapeutic targets. The platform is supported by a network of genomic partnerships with underrepresented populations globally. Variant Bio's therapeutic pipeline includes programs at various stages focused on inflammation, fibrosis, and kidney diseases. The company also provides data generation services using gold-standard platforms (Illumina, Olink, Metabolon) and maintains strategic collaborations with pharmaceutical partners including Boehringer Ingelheim and Novo Nordisk.

Differentiator

Problem solved

Functional benefit

Products and services

  • Inference Platform (VB-Inference)
  • Therapeutic Pipeline
  • Data Generation Services
  • Genomic Research Partnerships

Quantifiable outcome

  • Drugs supported by human genetics are over twice as likely to succeed in clinical trials
  • +2 more outcomes

Companies that use Variant Bio

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Variant Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Variant Bio partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and major.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 6 January 2026Variant Bio entered a multi-year research collaboration and license agreement with Boehringer Ingelheim to discover and validate novel drug targets for cardiorenal and kidney disease using the Inference AI platform. Variant Bio is eligible to receive upfront, license, and milestone payments totaling over $120 million SEK, with total collaborations exceeding $200 million. The partnership leverages Boehringer Ingelheim's extensive expertise in breakthrough medicine R&D.
  • Novo NordiskcoreStrategic or Co-development Partner · 7 January 2025Variant Bio launched a multi-year research partnership with Novo Nordisk to identify and validate novel targets with strong genetic evidence for the treatment of metabolic disease. The project leverages Variant Bio's Inference analysis platform and expertise partnering with global populations, as well as Novo Nordisk's vast experience in metabolic disease drug discovery. A notable feature of this partnership is that Novo Nordisk agreed to Variant Bio's benefit-sharing commitments with partner communities.
  • EvotecmajorStrategic or Co-development Partner · 18 April 2024Variant Bio entered a strategic partnership with Evotec to elucidate a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the program toward selection of clinical development candidate(s). The collaboration leverages Variant Bio's cutting-edge genomic discovery capabilities and Inference platform as well as Evotec's extensive expertise in antifibrotic drug discovery.
  • University of Antananarivo (Madagascar)coreStrategic or Co-development PartnerResearch collaboration with the Department of Anthropobiology and Sustainable Development led by Dr. Rindra Rakotoarivony, Pr. Germain Jules Spiral, and Dr. Jean Freddy Ranaivoarisoa. Partnership with Malagasy communities from three villages to understand human genetic diversity in Madagascar.
  • University of the Witwatersrand (South Africa)coreStrategic or Co-development PartnerCollaboration with the Sydney Brenner Institute for Molecular Bioscience at Wits University, building on the H3Africa AWI-Gen Collaborative Centre. Partnership with communities in Mpumalanga (Agincourt), Gauteng (Soweto), and Limpopo (DIMAMO) to create an eQTL database for understanding gene regulation across South African populations.
  • African Research on Kidney Disease (ARK) ConsortiumcoreStrategic or Co-development PartnerCollaboration with Dr. June Fabian (Wits Donald Gordon Medical Centre) and co-investigators Profs. Michèle Ramsay and Stephen Tollman. Working with rural communities in Mpumalanga to understand kidney disease burden, causes, and prevention in Sub-Saharan African populations.
  • Bilh i Genetics (Uganda)coreStrategic or Co-development PartnerPartnership with Bilhi Genetics, founded by Dr. Alain Dessein, to identify genetic risk factors for severe liver fibrosis among communities in the West Nile region of Uganda, where schistosoma parasite infection is highly prevalent.
  • George Institute for Global Health IndiacoreStrategic or Co-development PartnerCollaboration with Professor Vivekanand Jha's Kidney Research Team to investigate the genetics of chronic kidney disease in the Uddanam region of Andhra Pradesh, India, an area with high CKD prevalence.
  • National Institute of Mental Health and Neuro Sciences (NIMHANS, India)coreStrategic or Co-development PartnerPartnership with Drs. Atchayaram Nalini and Gautham Arunachal Udupi for the first population-scale genomic study of ALS in India, aiming to understand frequencies of known genetic variants and discover new variants associated with ALS across Indian ethnic groups.
  • Mochtar Riady Institute for Nanotechnology (Indonesia)coreStrategic or Co-development PartnerCollaboration with the Genome Diversity and Diseases Research Group led by Dr. Herawati Sudoyo and Dr. Safarina Malik. Partnership with communities from six ethnic groups across the Indonesian archipelago and expanded to samples from over 70 ethnic groups, combining genetics, functional genomics, metabolomics, and clinical data.
  • FarGen & University of Copenhagen (Faroe Islands)coreStrategic or Co-development PartnerPartnership with FarGen (Faroe Genome Project, managed by Fólkaheilsustýrið) and Dr. Fernando Racimo from the University of Copenhagen. The Faroese population exhibits increased prevalence of cystic fibrosis, autoimmune disorders, and multiple sclerosis. Goal is to create a genetic reference panel representing the Faroese people for precision medicine.
  • University of Otago (Aotearoa New Zealand)coreStrategic or Co-development PartnerCollaboration with Dr. Tony Merriman for studies of metabolic disease (gout, kidney disease, diabetes) in people of Māori and Pacific ancestry, where these conditions are 2-3-fold more prevalent. Also a specific Pukapuka community study in Auckland focusing on genetics of gout and kidney disease.
  • Groupement des Hôpitaux de l'Institut Catholique de Lille (French Polynesia)coreStrategic or Co-development PartnerPartnership with Professor Tristan Pascart and the French Polynesian Ministry of Health for a large genetic study of gout across seven islands spanning French Polynesia's five archipelagos. Gout is especially frequent among Indigenous Pacific populations.
  • Queensland University of Technology (Norfolk Island)coreStrategic or Co-development PartnerPartnership with Professor Lyn Griffiths' Norfolk Island Health Study, expanding into new clinical areas and focusing on determining the burden of kidney disease, its causes, and prevention in the Norfolk Island community.
  • University of Alabama at BirminghamcoreStrategic or Co-development PartnerCollaboration with Dr. Tony Merriman and lab members for gout GWAS analyses and therapeutic target validation in gout based on prior genomic studies with Polynesian populations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Variant Bio competitors and assessment

Company assessment

Direct peers

  • BenevolentAI: AI platform that mines biomedical and genomic knowledge graphs to surface and validate novel drug targets; comparable AI-for-target-discovery value proposition with pharma partnerships.
  • Insitro: AI/ML-driven drug discovery company combining machine learning with cellular and genetic data to identify and validate therapeutic targets; pursues pharma partnerships similarly to Variant Bio.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company using computational methods to accelerate target identification and partner with large pharma; direct competitive overlap in AI-genomics for therapeutics.
  • Exscientia: AI-driven drug design company with pharma partnerships for target identification and small-molecule design; comparable AI-discovery platform play serving similar pharma customers.
  • Recursion Pharmaceuticals: AI-enabled biotech that combines high-throughput biology with machine learning for target discovery and enters multi-year pharma collaborations; overlaps with Variant Bio's enterprise licensing motion.
  • Schrödinger: Computational chemistry and biology platform serving pharma customers with target prioritization and molecular design; competes for similar pharma AI-discovery budgets.

Emerging players

  • Owkin: AI-biomedicine platform that partners with academic medical centers and pharma to discover targets using multimodal patient data; intersects with Variant Bio's B2B pharma collaboration model.
  • Absci: AI-driven biologic drug creation company combining generative AI with wet-lab validation; overlaps with Variant Bio's computational biology approach to therapeutic development.
  • Generate Biomedicines: Generative AI platform for designing novel therapeutic proteins and biologics; partially overlapping in AI-biology-for-drug-discovery with a focus on generative rather than genetics-driven target ID.
  • Verge Genomics: AI-driven drug discovery using human genomics data to identify targets; comparable genetics-first approach though concentrated in neurodegenerative disease.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Variant Bio social profiles

Digital presence

Variant Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Variant Bio leadership team

Management profile

Number of profiles

Profiles6 records

Variant Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Variant Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Variant Bio

What does Variant Bio do?

Variant Bio develops life-saving therapies by leveraging human genetic diversity from underrepresented global populations. The company operates the Inference (VB-Inference) agentic AI-powered genomics platform, which integrates whole genome sequencing with deep phenotyping and multi-omics data to identify and validate novel therapeutic targets. It monetizes these discoveries through multi-year research collaborations and licensing agreements with large pharmaceutical companies, earning upfront fees, development milestones, and potential royalties on commercialized products.

Is Variant Bio a public or private company?

Variant Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Variant Bio founded?

Variant Bio was founded in 2018. It employs 11 to 50 people.

Where is Variant Bio based?

Variant Bio is headquartered in Seattle, United States, in the North America region.

How does Variant Bio make money?

Three revenue lines are on record. Pharmaceutical Licensing & Milestone Payments are the primary driver. The others are platform Access & Data Licensing and grant Funding.

Who are Variant Bio's main competitors?

Direct peers on record are BenevolentAI, Insitro, Isomorphic Labs, Exscientia, Recursion Pharmaceuticals and Schrödinger. Emerging players are Owkin, Absci, Generate Biomedicines and Verge Genomics.

Does Variant Bio have an API?

No public API is recorded for Variant Bio.

What industry is Variant Bio in?

Variant Bio's product category is Genomics Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyVariant Bio extends AI genetics deal to the heartVariant Bio and Boehringer Ingelheim expanded their collaboration to cardiovascular disease, using Variant Bio's AI platform to find drug targets. The deal includes an upfront payment plus license and milestone payments, potentially exceeding $250 million. No specific targets or clinical drugs were disclosed.Longevity.TechnologyVariant Bio expands AI target discovery deal with Boehringer Ingelheim into heart diseaseVariant Bio expanded its multi-year research collaboration with Boehringer Ingelheim to include cardiovascular disease, building on prior kidney disease work. The expanded terms include an additional upfront payment and license/milestone payments potentially exceeding $250 million. The partnership pairs Variant Bio's AI-driven Inference platform with Boehringer Ingelheim's disease expertise.European BiotechnologyBoehringer pays up to $250M to expand Variant Bio’s pact into heart diseaseBoehringer Ingelheim expanded its partnership with Variant Bio into cardiovascular disease, adding potential payments exceeding $250 million. The deal builds on a kidney disease collaboration and seeks genetically supported targets for first-in-class treatments. No upfront amount or development timeline was disclosed.The future of tradingVariant Bio Expands Target Discovery Collaboration With Boehringer Ingelheim Into Cardiovascular DiseaseVariant Bio expanded its target discovery collaboration with Boehringer Ingelheim into cardiovascular disease. The deal includes additional upfront, platform access, and milestone payments, with a total value potentially exceeding $250 million.FierceBiotechBoehringer adds $250M to value of Variant pact by expanding into cardiovascular diseaseBoehringer Ingelheim expanded its collaboration with Variant Bio to cover cardiovascular disease, potentially adding over $250 million in value. The deal includes an additional upfront payment and potential license and milestone payments. The companies aim to identify genetically supported targets for new cardiovascular treatments.PR NewswireVariant Bio Expands Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular DiseaseVariant Bio expanded its multi-year collaboration with Boehringer Ingelheim to apply its AI-powered Inference platform to cardiovascular target discovery. The deal includes additional upfront and milestone payments, potentially exceeding $250 million. The companies aim to identify genetically supported targets for new cardiovascular treatments.DrugdiscoverytrendsBlazing new paths for biotechAmerican biotech firms face an increasingly challenging environment as U.S. regulators and investors have grown more cautious, while China has streamlined its regulatory system to attract capital and accelerate drug development. The article presents three strategic approaches U.S. biotech companies are using to maintain competitive advantage: keeping products secret until the last possible minute (Variant Bio), leveraging commodified modalities through combination drugs for superior efficacy (Spyre Therapeutics, Kailera), and developing novel biomanufacturing platforms (Lumen Bio). The author argues that the key to American biotech's competitive edge lies in the artful balancing of tradeoffs among these three approaches to differentiation and cost efficiency.FierceBiotechADCs, TCEs among ‘exciting things’ on Boehringer’s dealmaking shopping listBoehringer Ingelheim has been aggressively pursuing licensing deals in early 2026, signing agreements worth up to $1.26 billion with companies including Variant Bio, Rectify Pharmaceuticals, Simcere, and Sitryx for cardiorenal, kidney, inflammatory bowel disease, and autoimmune disease programs. The German pharma company, which spent €7.4 billion on R&D last year (22.9% of sales), is prioritizing T-cell engagers and antibody-drug conjugates as key pipeline expansion areas, with its DLL3/DC3 TCE obrixtamig currently in Phase 3 for small-cell lung cancer. Boehringer is awaiting Phase 3 obesity data for survodutide, its GLP-1/glucagon agonist partnered with Zealand Pharma, after mid-stage trials showed nearly 19% weight loss and significant improvement in metabolic dysfunction-associated steatohepatitis (MASH).Drug Target ReviewNew AI genomics platform targets kidney and cardiorenal diseaseVariant Bio has launched Inference, the world's first agentic AI-powered genomics platform for drug discovery, developed over seven years with over $100 million invested. The Seattle-based biotech company simultaneously announced a multi-year research collaboration with Boehringer Ingelheim to discover novel targets for cardiorenal and kidney diseases, with potential payments exceeding $120 million. The platform aims to transform how pharmaceutical R&D teams harness human genetic data to discover and validate therapeutic targets for conditions affecting more than 850 million people globally.Precedence ResearchAI-Driven Genetics Platform Redefines Drug DiscoveryVariant Bio announced the release of a new AI-powered platform that uses genetic data to accelerate drug discovery by evaluating human genomic data to identify potential therapeutic targets more quickly than conventional methods. The company has entered a partnership with Boehringer Ingelheim to use the platform for finding novel treatments for kidney disease, with the agreement including upfront payments and possible future milestone-based earnings. The release positions Variant Bio at the forefront of data-driven, genetics-first drug development as the pharmaceutical industry increasingly adopts AI to modernize research.